Core Viewpoint - Yunqi Capital, a 5.1% shareholder of Staar Surgical Company, opposes the proposed sale of the company to Alcon based on the terms announced on August 5 [1] Group 1 - Yunqi Capital believes the sale price of $28 per share is inadequate [1]

Core Viewpoint - The Ademi Firm is investigating STAAR for potential breaches of fiduciary duty and other legal violations related to its transaction with Alcon Inc, where STAAR shareholders will receive $28 per share in cash, valuing the transaction at approximately $[1] Group 1 - The investigation by the Ademi Firm focuses on possible breaches of fiduciary duty by STAAR in its dealings with Alcon Inc [1] - Shareholders of STAAR are set to receive $28 per share in cash as part of the transaction [1] - The total valuation of the transaction is approximately $[1]

Financial Data and Key Metrics Changes - The company's second quarter sales reached $2.6 billion, reflecting a 3% increase year-over-year, consistent with the first quarter performance [29] - Core gross margin for the second quarter was 62.2%, in line with the previous year, while core operating margin decreased by 100 basis points to 19.1% due to increased R&D investments [32] - Core diluted earnings per share were $0.76, broadly in line with the previous year on a constant currency basis [32] Business Line Data and Key Metrics Changes - Surgical franchise revenue increased by 1% year-over-year to $1.5 billion, with implantable sales down 2% to $456 million due to soft market conditions and competitive pressures [29] - Vision Care sales rose by 5% to $1.1 billion, driven by a 7% increase in contact lens sales, primarily due to product innovation and price increases [30] - Oculo Health sales were up 2% year-over-year to $430 million, led by eye drop products, although there were declines in contact lens care [31] Market Data and Key Metrics Changes - Global cataract volumes grew approximately low single digits in the second quarter, compared to a historical average of about 4% [27] - The retail market for contact lenses grew mid single digits during the same period [27] Company Strategy and Development Direction - The company is focused on acquiring transformative technologies in eye care, with recent acquisitions including the Voyager Direct device for glaucoma and STAR for refractive surgery [10][11] - The company aims to leverage its broader commercial infrastructure to accelerate adoption of new products and expand its presence in growing markets like China [13][14] - The company is committed to driving organic growth through innovation and execution, with several major product launches underway [9][18] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that while the second quarter results fell short of expectations, they remain confident in the long-term durability of end markets and the resilience of customers [8][9] - The company expects to see sales growth accelerate in the second half of the year, particularly in the fourth quarter, despite current market softness [35] - Management emphasized the importance of innovation and operational discipline to drive long-term growth and shareholder value [40][38] Other Important Information - The company incurred $27 million in tariff-related charges during the second quarter, with an expected full-year impact of approximately $100 million on cost of sales [33] - The company is maintaining its core diluted earnings guidance range of $3.05 to $3.15 per share, reflecting a year-over-year change of 2% in constant currency [37] Q&A Session Summary Question: Can you elaborate on the stability of PCIOL share in the U.S. and the situation outside the U.S.? - Management noted a sequential improvement of about four share points in the U.S. market, attributed to the positive reception of PanOptix Pro, while acknowledging competitive pressures in international markets [46][48] Question: What is the outlook for market weakness and its recovery? - Management expressed confidence in the long-term growth of the cataract market, citing an increasing prevalence of cataracts and treatment access, despite current procedural volume oscillations [56][58] Question: How is the Unity VCS performing since its launch? - Management reported over 1,000 qualified leads for Unity VCS within ten weeks of launch, emphasizing a deliberate ramp-up process to ensure proper training and installation [62][64] Question: What is the expected sustainable revenue growth rate for the EVO ICL platform? - Management indicated a solid outlook for EVO in China and elsewhere, emphasizing the low penetration of EVO relative to high myopes and the importance of training and business model adjustments [103] Question: How is the company addressing increased tariff headwinds? - Management highlighted that the weak dollar is a significant mitigation factor, while also considering potential adjustments to the manufacturing footprint in response to tariff pressures [105][106]

Financial Data and Key Metrics Changes - Alcon's Q2 2025 sales reached $2.6 billion, reflecting a 3% increase year-over-year, consistent with Q1 performance [27] - Core gross margin for Q2 was 62.2%, in line with the previous year, while core operating margin decreased by 100 basis points to 19.1% due to increased R&D investments [31] - Core diluted earnings per share were $0.76, broadly in line with the previous year on a constant currency basis [31] Business Line Data and Key Metrics Changes - Surgical franchise revenue increased by 1% year-over-year to $1.5 billion, with implantable sales down 2% to $456 million due to soft market conditions and competitive pressures [27][28] - Vision Care sales rose by 5% to $1.1 billion, with contact lens sales up 7% to $692 million, driven by product innovation and price increases [29] - Oculo Health sales were $430 million, up 2% year-over-year, led by eye drops, partially offset by declines in contact lens care [30] Market Data and Key Metrics Changes - Global cataract volumes grew approximately low single digits in Q2, compared to a historical average of about 4% [25] - The retail market for contact lenses grew mid single digits during the quarter [25] Company Strategy and Development Direction - Alcon is focused on acquiring transformative technologies in eye care, with recent acquisitions including the Voyager Direct device for glaucoma and STAR for refractive surgery [8][9] - The company aims to leverage its broader commercial infrastructure to accelerate adoption of new products and expand its presence in high-growth markets like China [11][12] - Alcon's strategy includes driving organic growth through innovation and execution, with a robust pipeline and strategic expansion planned for 2026 and beyond [7][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term durability of end markets and the resilience of customers despite softer market conditions in the first half of the year [6][7] - The company anticipates a gradual return to historical growth rates in surgical procedures, driven by an aging population and increasing cataract prevalence [57][58] - Alcon expects to fully offset tariff impacts through foreign exchange and operational actions, maintaining a focus on innovation and cost discipline [32][33] Other Important Information - Alcon generated $681 million in free cash flow in the first half of the year, enabling $287 million in returns to shareholders through share repurchases and dividends [32] - The company incurred $27 million in tariff-related charges during Q2, with an expected full-year impact of approximately $100 million on cost of sales [32] Q&A Session Summary Question: Stability in PCIOLs share in the U.S. and international markets - Management noted a sequential improvement in U.S. share by about four points, attributed to the successful reception of PanOptix Pro, while acknowledging competitive pressures in international markets [43][46] Question: Outlook for 2026 and impact of recent acquisitions - Management refrained from providing specific guidance for 2026 but expressed confidence in the strategic value of recent acquisitions, emphasizing the importance of synergies and operational support [51][53] Question: Market weakness and outlook for recovery - Management highlighted that the aging population and increasing cataract prevalence underpin confidence in future growth, despite current market normalization [57][58] Question: Unity VCS order book and placements - Management reported over 1,000 qualified leads for Unity VCS within ten weeks of launch, emphasizing a deliberate ramp-up in installations to ensure proper training and support for surgeons [62][64] Question: Performance of SUSTAIN and competitive dynamics - Management indicated mid to high single-digit growth for SUSTAIN, noting a market pop due to competitor advertising, while addressing supply issues affecting some products [92][94] Question: Growth outlook for STAR and local competition in China - Management acknowledged local competition in China but expressed confidence in the long-term growth potential of the EVO ICL platform, supported by Alcon's critical mass and market presence [96][99]

Acquisition - Alcon will acquire STAAR Surgical for \$28 per share in cash, representing a ~59% premium to STAAR's 90-day volume-weighted average price[15] - The acquisition represents a total equity value of approximately \$1.5 billion and is expected to be funded through short- and long-term credit facilities[15] - The acquisition is expected to be accretive to core diluted EPS in year two[15] Financial Highlights (Q2 2025) - Net sales reached \$2.6 billion, a 4% increase year-over-year on a reported basis and a 3% increase in constant currency[21] - Core operating margin was 19.1%, a decrease of 70 basis points[21] - Core diluted EPS was \$0.76, compared to \$0.74 in Q2 2024[20] Financial Highlights (1H 2025) - Net sales reached \$5.0 billion[26] - Free cash flow was \$681 million[20] Product Mix (1H 2025 Sales) - Vision Care accounted for 45% (\$2.2 billion) of sales, while Surgical accounted for 55% (\$2.8 billion)[27] - Within Vision Care, contact lenses represented 62% of sales[27] - Within Surgical, consumables represented 53% of sales[27] FY 2025 Outlook (Updated) - Net sales are projected to be between \$10.3 to \$10.4 billion[64] - Core operating margin is expected to be between 19.5% to 20.5%[64] - Core diluted EPS is maintained at \$3.05 to \$3.15[64]

Core Insights - Staar Surgical's international revenue performance is critical for assessing its financial resilience and growth prospects [1][2][3] Group 1: Financial Performance - The company's total revenue for the quarter was $44.32 million, a decline of 55.2% year over year [4] - Other International contributed $18.18 million, accounting for 41% of total revenue, which was a surprise of -24.34% compared to the consensus estimate of $24.03 million [5] - Japan generated $10.92 million, representing 24.6% of total revenue, with a positive surprise of +8.28% compared to the projected $10.08 million [6] - China accounted for 12% of total revenue, translating to $5.3 million, with a significant surprise of +454.87% against the expected $0.96 million [7] Group 2: Future Revenue Predictions - For the current fiscal quarter, analysts anticipate total revenues of $89.27 million, reflecting a 0.8% increase year over year [8] - Expected revenue contributions for the current quarter are 23.8% from Other International ($21.26 million), 12.8% from Japan ($11.38 million), and 54.2% from China ($48.36 million) [8] - For the full year, total revenue is projected to be $258.21 million, down 17.7% from the previous year, with specific contributions from Other International (36.1%), Japan (17.3%), and China (36.9%) [9] Group 3: Market Context - Staar Surgical's reliance on international markets presents both opportunities and challenges, necessitating close monitoring of international revenue trends [10] - The interconnected global economy and geopolitical factors are increasingly influencing earnings predictions for companies with overseas operations [10][11]

Investment Rating - The report maintains a positive investment outlook on innovative drugs and medical devices, highlighting them as key investment themes in the current market environment [2][4][43]. Core Insights - The report emphasizes the ongoing support from the government for innovative medical drugs and devices, particularly in the brain-computer interface (BCI) sector, which is expected to see significant advancements by 2027 and 2030 [1][51]. - The innovative drug sector remains a primary investment focus, with a recommendation to pay attention to leading pharmaceutical companies' transformation results and their opportunities for international expansion [2][43]. - The report identifies a growing interest in innovative medical devices, driven by favorable policies and a recovery in medical equipment procurement trends, suggesting a potential performance turnaround in the second half of the year [4][12]. Summary by Sections Innovative Drugs - The innovative drug sector is highlighted as a key investment line, with a focus on potential blockbuster drugs and collaborations for innovative drug development [2][43]. - The report notes that after multiple rounds of generic drug procurement, risks for leading pharmaceutical companies are gradually being alleviated, revealing competitive innovative drug pipelines [2][43]. Biological Products - Anke Biotech's subsidiary has received approval for a shingles mRNA vaccine, indicating progress in the mRNA drug development space [2][45]. - The report suggests continued monitoring of Anke Biotech's collaboration with its subsidiary and the advancements in mRNA drug development [2][50]. Medical Devices - The report discusses the government's support for the BCI industry, which is expected to accelerate commercialization and product development [1][3]. - It highlights the recovery trend in medical device procurement and the increasing market share of leading companies, indicating a strong performance outlook for the sector [4][12]. Traditional Chinese Medicine - Some traditional Chinese medicine companies are in a good cash flow position and are expected to see growth through innovative product pipelines and strategic investments [3][19]. Medical Services and Consumer Healthcare - The report notes a series of positive earnings announcements from high-growth stocks in the medical services sector, indicating a robust growth outlook [3][4].

Core Viewpoint - Monteverde & Associates PC is investigating the proposed sale of STAAR Surgical Company to Alcon Research LLC, where STAAR shareholders are set to receive $28.00 in cash per share, raising questions about the fairness of the deal [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is located in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Transaction Details - The proposed transaction involves STAAR Surgical Company selling to Alcon Research LLC, with shareholders receiving $28.00 per share [1]. - The investigation aims to determine if the deal is fair for STAAR shareholders [1].

Core Insights - Staar Surgical reported a revenue of $44.32 million for the quarter ended June 2025, marking a year-over-year decline of 55.2% and an EPS of -$0.07 compared to $0.33 a year ago, indicating significant financial challenges [1] - The revenue exceeded the Zacks Consensus Estimate of $41.56 million by 6.63%, while the EPS surprise was 87.5% against a consensus estimate of -$0.56, suggesting better-than-expected performance in terms of earnings [1] Revenue Performance - Net Geographic Sales in the United States were $5.64 million, slightly below the average estimate of $6.46 million, reflecting a year-over-year increase of 4.4% [4] - Net Geographic Sales from Other International markets totaled $18.18 million, significantly lower than the average estimate of $24.03 million, showing a year-over-year decline of 10.6% [4] - Sales in Japan reached $10.92 million, surpassing the average estimate of $10.08 million with a year-over-year increase of 10.4% [4] - In China, sales were reported at $5.3 million, a dramatic drop from the average estimate of $0.96 million, representing a year-over-year decline of 91.6% [4] Stock Performance - Staar Surgical's shares have returned +59.8% over the past month, significantly outperforming the Zacks S&P 500 composite, which saw a change of +0.5% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Company Performance - Staar Surgical reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.56, representing an earnings surprise of +87.50% [1] - The company posted revenues of $44.32 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.63%, although this is a decline from year-ago revenues of $99 million [2] - Over the last four quarters, Staar Surgical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Movement and Outlook - Staar Surgical shares have increased by approximately 11.2% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the earnings outlook for the upcoming quarters [3][4] - The current consensus EPS estimate for the next quarter is $0.18 on revenues of $87.83 million, while for the current fiscal year, it is -$0.78 on revenues of $258.21 million [7] Industry Context - The Medical - Dental Supplies industry, to which Staar Surgical belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Staar Surgical's stock may also be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]